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Fragment-oriented synthesis: b-elaboration of
cyclic amine fragments using enecarbamates as
platform intermediates†
Alexandre F. Trindade,a Emily L. Faulkner, a Andrew G. Leach, b
Adam Nelson *ac and Stephen P. Marsden *a
A strategy for the b-sp3 functionalisation of cyclic amines is
described. Regioselective conversion of protected amines to ene-
carbamates is achieved through electrochemical oxidation; these
intermediates can be derivatised by functionalised alkyl halides
under photoredox catalysis. The potential of the methods is high-
lighted by direct growth of a DCP2B-binding fragment.
Fragment-based ligand discovery is well established as a power-
ful approach for the discovery of new drugs, with four mole-
cules developed in this way in clinical usage and many more in
advanced trials.1 Fragments are typically smaller molecules
than those used in high-throughput screening, meaning they
explore chemical space more efficiently and, while the absolute
potency of hit molecules is generally low, they bind their targets
with high ligand efficiency (binding energy per non-hydrogen
atom). A key step in the process is to ‘grow’ fragment hits from
potentially any position without disrupting existing favourable
binding interactions, in order to improve potency whilst pre-
serving high ligand efficiency.2
Medicinal chemistry is dominated by a limited reaction toolkit
that is heavily focused on heteroatom functionalisation.3 Given the
strict molecular weight constraints applied to fragments, there are
usually limited opportunities to grow them by elaborating
functional groups that are not engaged in binding interactions.4
Fragment growth thus frequently requires time- and resource-
intensive de novo synthesis, and can become a bottleneck in
discovery.5 This is illustrated in the discovery of 1 (Fig. 1, panel
A), a sub-micromolar lead compound against X-linked Inhibitor
of Apoptosis Protein.6 Analysis of the binding pose of the low
potency fragment hit 2 by protein crystallography identified
elaboration of the 2- and 5-positions of the piperazine ring as
key opportunities. The preparation of the lead compound 1
necessitated multi-step de novo synthesis of the disubstituted
piperidine core.
A more attractive alternative would be to directly elaborate
the hit fragment or a closely-related ‘stock’ precursor. In this
context, C–H functionalisation chemistry presents an attractive
opportunity to decorate otherwise inert atoms, and the many
methods developed for direct functionalisation of sp2 C–H
bonds7 complements the wide availability of sp2-rich fragments.
Given their ubiquity in drug molecules and other bioactives,8
saturated cyclic amines are attractive sub-structures within sp3-
rich fragments. Many methods have been developed for direct
functionalization of saturated cyclic amines a-to nitrogen9 and
indeed a recent report describes a-amino radical generation/Min-
isci heteroarylation as a means of selective a-functionalisation of
protected cyclic amines in the context of fragment growth.10 By
contrast, however, methods for the b- and g-functionalisation
of cyclic amines are much less common,11 meaning fragment
growth along these vectors would likely fall back upon scaffold
re-synthesis.
Fig. 1 De novo synthesis versus direct fragment elaboration.
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We envisaged that oxidation of protected cyclic amines to
enamides or enecarbamates would afford a platform for the
elaboration of fragment hits such as 3 at the b-position with a
variety of functional groups, circumventing the need for de novo
synthesis (Fig. 1, panel B). The utility of this process would rest
both upon the efficient generation of the unsaturated amine
derivatives, and the ability to introduce medicinally-relevant
functionality to the b-carbon. We describe here the successful
development of this approach.
Carbamate-protected amines would be useful precursors to
fragments in which the nitrogen is either undecorated or,
through N-functionalisation, a point of diversity, and so we
sought methods to convert such species into enecarbamates.
Employing the anodic oxidation first described by Shono,12
N-Cbz piperidine 4a gave excellent conversion into methyl
aminoacetal 5a (isolable in 90% yield). Attempted elimination
failed using Brønsted acid12b,13 but the combination of TMSOTf
and Hunig’s base gave clean conversion to enecarbamate
6a (unoptimised 65% yield).14 Gratifyingly, the steps could be
telescoped, giving 6a in 90% yield after purification. The
protocol was extended to other carbamates (Scheme 1).
The method proved robust across a broad range of substrates,
encompassing various ring sizes (e.g. 6a–c), the presence of
b-heteroatoms (6g,h) and a range of appended substituents includ-
ing arenes (6e,m), esters (6i,j,n), secondary carbamates (6o) and
heteroarenes (6p). The oxidation of unsymmetrical substrates
introduces the challenge of regiocontrol. With 2-substituted car-
bamates, literature precedent supports the predominant for-
mation of the less-substituted 2,n-aminoacetals (although the
origin of this selectivity remains unclear)15 and we did indeed
observe formation of the less-substituted enecarbamates 6j and 6k.
The prospects for regiocontrol from more distal substituents
seemed less encouraging, but we were delighted to find reactions
of 3-substituted piperidines were often also highly selective. Of the
five substrates investigated, four gave single regioisomers of the
isolated enecarbamates 6m–p; the reaction of N-Cbz-3-
methylpiperidine was less selective, with the less-substituted
regioisomer 6l dominating in an inseparable 2 : 1 mixture. The
origin of this regioselectivity was probed through DFT calculations
(M06-2X/6-31+G** level of theory; see ESI†). The proposed mecha-
nism involves formation of an (alkoxycarbonyl)amino radical
cation, which undergoes proton loss to generate a-amino radicals;
subsequent one-electron oxidation gives the corresponding imi-
nium ions (Fig. 2). Radical A, leading to the observed favoured
iminium ion, is higher in energy than radical B in both the gas
and solution phase. Conversely, the observed iminium ion A is
lower in energy than iminium B in the solution phase (moderate
preference for B in the gas phase), but invoking iminium stability
as the origin of the selectivity requires equilibration of the two
isomers. We favour instead a kinetic explanation: modelling the
transition states for solvent-mediated deprotonation of the (alkox-
ycarbonyl)amino radical cation revealed path A was favoured in
both the gas (98 : 2) and solution (92 : 8) phase. The corresponding
calculations with the 3-methyl variant showed a modest prefer-
ence for path B (observed ratio within the intrinsic error of the
calculations), supporting the lower observed selectivity. The origin
of the selectivity is therefore likely steric.
We now turned our attention to methods for elaboration of the
enecarbamates to facilitate fragment growth along the valuable
vector from the b-carbon atom. Specifically, we targeted introduc-
tion of functionalised alkyl groups capable of making additional
beneficial interactions with a target protein by coupling of
a-functionalised alkyl radicals with the enecarbamates as acceptor
alkenes. While the coupling of enamides and enecarbamates has
been reported with bromomalonates and bromoketoesters,16
reactions of the more useful monoactivated electrophiles (e.g.
bromoacetates) have only been reported with highly nucleophilic
enamines17,18 and their coupling with secondary enamides or
enecarbamates has not been demonstrated to date.19 We there-
fore investigated the coupling of ethyl bromoacetate with enecarb-
amate 6a and pleasingly, following limited optimisation (ESI†),
we identified Ir(ppy)3 as an effective photocatalyst for the reaction.
In methanol as solvent, the initial product of the reaction was
aminoacetal 7a; subsequent treatment of this crude material with
triethylsilane in the presence of BF3 etherate gave substituted
Cbz-piperidine 8a in 92% isolated yield (Scheme 2). In addition,
the reaction also worked with N-acetyl and N-benzoyl enamides
(ESI†), demonstrating the feasibility of direct elaboration of
amide-containing fragments.
We next investigated substrate scope and found that enecarb-
amates derived from piperidines, azepanes, morpholines, oxa-
zepanes and diazepanes are all suitable partners in the reaction
(e.g. 8a–8e). However, Cbz-dihydropyrrole did not return the
desired product, which we attributed to oxidative decomposition
via Cbz-pyrrole. Consistent with this, blocking oxidation through
Scheme 1 Formation of enecarbamates by electrochemical oxidation/
elimination. * 2 : 1 mixture of alkene regioisomers.
Fig. 2 Regioselectivity in electrochemical carbamate oxidation.
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a,a-disubstitution allowed generation of substituted pyrrolidine
8f. Substitution on the aliphatic backbone of the enecarbamates
was tolerated, allowing access to 2,5-, 3,5- and 3,4-disubstituted
piperidine products such as 8g–j: even more notably, potentially
sensitive and medicinally relevant heteroatom-containing sub-
strates also performed well (e.g. 8m,n). Addition to more complex
bicyclic substrates was also successful, exemplified in the con-
struction of both bridged (8k) and fused (8o) products. Pleasingly,
alternative monoactivated alkyl electrophiles could also be utilised,
allowing for introduction of side-chains bearing ketone, nitrile and
sulfonyl substituents (see ESI†). Details of mechanistic studies can
be found in the ESI.†
Amides are present in ca. 25% of drug candidates and amide
bond formation is amongst the most widely used reactions in
drug discovery3b and development.20 The direct introduction of
amidoalkyl groups to fragments would therefore be valuable
but, despite extensive efforts, we were unable to achieve effi-
cient coupling of cyclic enecarbamates with a-bromoacetamides
(maximum 20% yield), possibly reflecting a more difficult
reduction to give a-acetamidyl radicals.21 We therefore consid-
ered an alternative approach wherein coupling of a suitably
activated ester electrophile would give an intermediate that
could undergo substitution with an amine to deliver the amide
in a telescoped process. As a further benefit, this approach
would enable the synthesis of arrays of elaborated fragments
from a single common activated ester intermediate. Pleasingly,
reaction of N-hydroxysuccinimidyl bromoacetate 9 with enecar-
bamate 6a using 2 mol% Ir(ppy)3 in acetonitrile gave clean
conversion into the substituted enecarbamate 10a in 77% NMR
yield (Scheme 3). Simple addition of two equivalents of an
amine and stirring led to the formation of the amidomethyl-
substituted enecarbamates 11 in good yield over the two-step, one-
pot sequence. The reactions worked well with a broad range of
primary and secondary aliphatic amines (panels a and b), including
hindered a-branched variants (e.g. 11a,j,k,o). Medicinally-relevant
substituents such as oxetanes (11k), morpholines (11n), (protected)
piperazines (11m) and azine heterocycles (11c) were also tolerated,
although reactions of (hetero)aromatic amines were unsuccessful
even under forcing conditions. We also demonstrated that the crude
enecarbamates could be directly reduced by exposure to Et3SiH and
TFA, giving the saturated derivatives 12a–f in good yield (panel c).
Scheme 2 Substrate scope of enecarbamates in photoredox-mediated
b-carboxyalkylation; ayield after N-Boc reprotection; bN-Boc protection
removed in reductive step.
Scheme 3 Synthesis of acetamidomethyl-substituted enamides by coupling of enecarbamates with activated esters. * Panel c only: the crude reaction
mixture was treated with triethylsilane and TFA in dichloromethane.
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Finally we wished to demonstrate the application of the
b-alkylation chemistry to the growth of a fragment hit. The
piperonyl azepane 3 (Fig. 1) has been found via high-
throughput X-ray crystallography to be a fragment hit for the
m7GpppN-mRNA hydrolase DCP2B.22 The carbon atoms b-to
the nitrogen have been identified as potential vectors for
fragment growth,22 yet 3-carboxalkyl-substituted azepanes are
not catalogue commodities,23 meaning de novo synthesis would
be inevitable to exploit this vector. Instead, we were able to
demonstrate introduction of a carboxymethyl group to enamide
13 by photoredox-mediated alkylation and reduction, giving
ester 14 in 59% yield (Scheme 4). Alternatively, amidoalkyl
groups could be introduced using the protocol via the inter-
mediate N-hydroxysuccinimidyl ester, giving e.g. amide 15 in
36% yield. We also used both approaches to effect late-stage
functionalization of the anti-depressant paroxetine (ESI†).
In summary, we have described methods for the challenging
b-functionalisation of cyclic amines through regioselective con-
version to enecarbamates and the subsequent installation of
medicinally-relevant carboxyalkyl functionalities. We have
further shown that the method can be used for regiospecific
growth of fragment hits and in late-stage functionalization of
complex products. The development of further methods for the
direct elaboration of enecarbamates with medicinally-relevant
functionality, as well as applications in fragment-based discov-
ery projects, are ongoing.
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Scheme 4 Direct fragment growth and late-stage functionalisation of
paroxetine using enecarbamate alkylation: (i) 2.2 mol% Ir(ppy)3, 3 equiv.
BrCH2CO2Me, 2,6-lutidine, MeOH, 32 W blue LED, 3 h; (ii) Et3SiH, BF3OEt2,
CH2Cl2; (iii) 2.2 mol% Ir(ppy)3, 3 equiv. 9, Na2HPO4, MeCN, 32 W blue LED,
5 h, then cC3H5NH2, 1 h; (iv) Et3SiH, TFA, CH2Cl2.
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